Lilly Expands Biotech Capabilities to Match Expanding Biotech Pipeline
First phase of $560 million complex completed
Eli Lilly and Company announced completion of the first phase of a $560 million expansion to its biotech complex in Indianapolis. The investment is part of a $1 billion effort to strengthen and build the company's biotechnology drug research and development capabilities.
At a ceremony at its Indianapolis operations, company officials dedicated a state-of-the-art bioproducts pilot manufacturing plant that shall help the company bring advanced biotech medicines to patients through more efficient, productive and dependable manufacturing processes. The company also announced the opening of a research support facility, into which 700 scientists, engineers and support staff will relocate.
Lilly initially announced plans for the biotechnology complex in 2002. In 2004, those plans were expanded to nearly twice their original size to better meet the company's pipeline of biotech drugs.
"Inside these new buildings, the latest in highly sophisticated technologies and equipment for conducting biotech research and development have been incorporated," said Steven Paul, M.D., Lilly's executive vice president of science and technology. "Taken together -- the facilities, the technologies, and an interdisciplinary approach -- we've created a new model for Lilly that gives the company a competitive advantage in bringing breakthrough medicines to patients in a more efficient, productive, and dependable manner."
Other news from the department manufacturing
